U.S. Markets open in 4 hrs
  • S&P Futures

    4,163.50
    +1.00 (+0.02%)
     
  • Dow Futures

    33,933.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    14,014.25
    +0.25 (+0.00%)
     
  • Russell 2000 Futures

    2,257.20
    +1.50 (+0.07%)
     
  • Crude Oil

    63.37
    -0.09 (-0.14%)
     
  • Gold

    1,764.90
    -1.90 (-0.11%)
     
  • Silver

    25.92
    -0.04 (-0.17%)
     
  • EUR/USD

    1.1973
    -0.0003 (-0.0240%)
     
  • 10-Yr Bond

    1.5300
    -0.1080 (-6.59%)
     
  • Vix

    16.57
    -0.42 (-2.47%)
     
  • GBP/USD

    1.3784
    -0.0001 (-0.0041%)
     
  • USD/JPY

    108.6920
    -0.0240 (-0.0221%)
     
  • BTC-USD

    61,043.40
    -1,785.36 (-2.84%)
     
  • CMC Crypto 200

    1,397.85
    +16.90 (+1.22%)
     
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • Nikkei 225

    29,642.69
    +21.70 (+0.07%)
     

AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study

Vandana Singh
·1 min read
  • AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.

  • The company reported no serious adverse events, thus paving the way for dose escalation in Cohort 2.

  • An independent institute in the Netherlands is conducting the clinical study AMP-COV-100 (CHDR2049) to evaluate the safety and activity of repeated intranasal administration of Ampligen in Healthy Subjects.

  • AIM is the sponsor and is funding the clinical study.

  • The study protocol calls for the enrollment of eight healthy subjects in each of four Cohorts to receive Ampligen. Two additional healthy subjects in each Cohort will receive a placebo for a total of 40 healthy subjects.

  • AIM will continue to provide interim updates on the clinical trial.

  • Price Action: AIM shares were trading 0.65% higher at $2.34 during market trading hours on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.